Activated partial thromboplastin time and anti-xa measurements in heparin monitoring biochemical basis for discordance

American Journal of Clinical Pathology

Volumn 139, Issue 4, 2013, Pages 450-456

  Takemoto, Clifford M ^a   Streiff, Michael B ^a   Shermock, Kenneth M ^a   Kraus, Peggy S ^a   Chen, Junnan ^a   Jani, Jayesh ^a   Kickler, Thomas ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti Xa levels; Endogenous thrombin potential; Heparin monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; HEPARIN; PROTHROMBIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG MONITORING; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; BLOOD; BLOOD CLOTTING TEST; METHODOLOGY;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME;

MLCS; MLOWN;

EID: 84877249391     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPS6OW6DYNOGNH     Document Type: Article

References (17)

1. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324-327.
2. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost. 1996;75:734-739.
3. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798.
4. Odegard OR, Lie M, Abilgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis. 1976;5:265-275.
5. Lehman CM, Rettman JA, Wilson LW, et al. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous unfractionated heparin. Am J Clin Pathol. 2006;126;416-421.
6. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the APTT: time for a fresh look. Thromb Haemost. 2006;96:547-552.
7. Neuenschwander PF, Williamson SR, Nalian A, et al. Heparin modulates the 99-loop of factor IXa: effects on reactivity with isolated Kunitz-type inhibitor domains. J Biol Chem. 2006;281:23066-23074.
8. Lehman CM, Frank EL. Laboratory monitoring of heparin: partial thromboplastin time or anti-Xa assay? Lab Med. 2009;40:47-51.
9. Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2011;87:194-196.
10. Ignjatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res. 2007;120:347-351.
11. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4-15.
12. Mehta BM, Kiani An, Chen C, et al. Endogenous thrombin potential in the assessment of hypercoagulation in systemic lupus erythematous. Am J Hematol. 2010;85:83-85.
13. Reiner AP, Lange LA, Smith NL, et al. Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study. J Thromb Haemost. 2009;9:1499-1505.
14. Al Dieri R, Alban S, Beguin S, et al. Thrombin generation for the control of UFH treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost. 2004;2:1395-1401.
15. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their significance and need for clinical and laboratory research. J Hepatol. 2007;46:727-733.
16. Duchemin J, Petesch BP, Arnaud B, et al. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost. 2008;99:767-773.
17. Al Dieri R, Peyvand F, Santasgostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002;88:576-582.